• Daclatasvir Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, Dihydrochloride Salt Tablet, packed exclusively in highly secure, moisture-resistant heavy-gauge HDPE bottles or Alu-Alu blister strips to ensure the absolute chemical survival of the active virological agent.

    Active IngredientStrengthPrimary Clinical Function
    Daclatasvir Dihydrochloride USP/Ph.Eur.60 mgThe Standard Eradication Macrodose: The definitive, globally standardized daily therapeutic payload utilized for the vast majority of patients to achieve a Sustained Virologic Response (SVR12 – Clinical Cure).
    Daclatasvir Dihydrochloride USP/Ph.Eur.30 mgThe CYP3A4 Titration Unit: The strict, mandatory dose-reduction unit utilized for patients who are co-infected with HIV and taking strong CYP3A inhibitors (like Ritonavir or Atazanavir).
    ExcipientsAnhydrous Lactose / Microcrystalline Cellulose / Croscarmellose Sodium / Silicon Dioxide / Magnesium Stearate / Premium Polymeric Film (Opadry Green)Diluent / Densifier / Superdisintegrant / Glidant / Heavy Film-Coating (Engineered specifically utilizing advanced dissolution-enhancing matrices to ensure the Dihydrochloride salt separates perfectly in gastric fluid, guaranteeing maximum systemic bioavailability)

    *Pack Sizes: Heavy-Gauge HDPE Bottles of 28 (Optimized exactly for a 4-week supply in strict 12-week or 24-week curative regimens).

  • Entacavir Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, High-Density Microdose Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute chemical stability of the potent antiviral API.

    Active IngredientStrengthPrimary Clinical Function
    Entecavir (as Monohydrate) USP/Ph.Eur.0.5 mgThe Global Nucleoside-Naive Standard: The definitive ultra-micro-dose utilized for the daily, lifelong suppression of HBV in patients who have never received prior antiviral therapy.
    Entecavir (as Monohydrate) USP/Ph.Eur.1.0 mgThe Refractory & Cirrhosis Standard: Double-strength therapeutic payload utilized specifically for patients with Lamivudine-resistant HBV viremia or those suffering from decompensated liver cirrhosis.
    ExcipientsLactose Monohydrate / Microcrystalline Cellulose / Crospovidone / Magnesium Stearate / Premium Polymeric FilmDiluent / Binder / Superdisintegrant / Lubricant / Film-Coating (Engineered specifically utilizing advanced multi-stage geometric dilution to ensure the microscopic 0.5mg payload is flawlessly distributed throughout the tablet matrix, preventing toxic “hot spots” or sub-therapeutic failures)

    *Pack Sizes: 3×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic hepatology dispensing regimens).

  • Furosemide & Spironolactone Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-PVC or Alu-Alu blister strips to ensure the absolute chemical stability of both active pharmaceutical ingredients.

    Active IngredientStrengthPrimary Clinical Function
    Furosemide USP/Ph.Eur.20 mgThe Loop Diuretic (Fluid Clearance): Rapidly eliminates severe fluid buildup (edema) from the lungs, abdomen, and peripheral tissues.
    Spironolactone USP/Ph.Eur.50 mgThe Potassium-Sparing Shield: Blocks aldosterone, prevents toxic cardiac fibrosis, and heavily protects the patient against lethal hypokalemia.
    ExcipientsMicrocrystalline Cellulose / Lactose Monohydrate / Sodium Starch Glycolate / Povidone K-30 / Magnesium Stearate / Premium Polymeric FilmDiluent / Binder / Superdisintegrant / Slipper-Coating (Engineered utilizing advanced wet-granulation to ensure both the rapid-acting Furosemide and the slower-acting Spironolactone dissolve at precise, synchronized rates to guarantee the electrolyte-sparing synergy)

    *Pack Sizes: 10×10 Blisters (Optimized specifically for strict chronic cardiology and hepatology dispensing regimens).

  • L- ornithine-L-aspartate tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-PVC or Alu-Alu blister strips to ensure the absolute chemical and physical stability of the highly hygroscopic amino acid salt.

    Active IngredientStrengthPrimary Clinical Function
    L-Ornithine L-Aspartate (LOLA)150 mg / 250 mgHepatology Maintenance Standard: Base therapeutic units for long-term chronic management of severe Non-Alcoholic Fatty Liver Disease (NAFLD), alcoholic hepatitis, and mild hyperammonemia.
    L-Ornithine L-Aspartate (LOLA)500 mgAcute Detoxification Standard: High-efficacy adult therapy utilized for immediate ammonia reduction and the step-down management of Hepatic Encephalopathy following hospital discharge.
    ExcipientsMicrocrystalline Cellulose / Crospovidone / Colloidal Silicon Dioxide / Magnesium Stearate / Premium Opadry Moisture-Barrier FilmDiluent / Superdisintegrant / Glidant / Film-Coating (Engineered specifically to lock out atmospheric moisture, preventing the heavy 500mg amino acid tablet from swelling, cracking, or prematurely degrading before it reaches the patient’s stomach)

    *Pack Sizes: 10×10 Blisters (Optimized specifically for strict, high-volume chronic hepatology dispensing regimens).

  • Ledipasvir & sofosbuvir Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, Dual-Active FDC Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles with specialized desiccants to ensure the absolute chemical survival of the complex antiviral APIs.

    Active IngredientStrengthPrimary Clinical Function
    Ledipasvir USP/Ph.Eur.90 mgThe NS5A Anchor: Potent inhibitor of viral assembly and secretion; highly effective against specific HCV genotypes.
    Sofosbuvir USP/Ph.Eur.400 mgThe NS5B Backbone: The globally recognized foundational DAA that forces viral RNA chain termination across multiple genotypes.
    ExcipientsCopovidone / Lactose Monohydrate / Microcrystalline Cellulose / Croscarmellose Sodium / Magnesium Stearate / Premium Opadry FilmBinder / Diluent / Superdisintegrant / Lubricant / Film-Coating (Engineered specifically to solve the massive solubility differences between the highly soluble Sofosbuvir and the poorly soluble Ledipasvir, guaranteeing synchronized gastric release and peak systemic absorption)

    *Pack Sizes: Bottles of 28 (Optimized specifically for the strict 4-week dispensing intervals required for 8, 12, or 24-week curative regimens).

  • Ledipasvir Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, Solid-Dispersion Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute chemical survival of the complex antiviral API.

    Active IngredientStrengthPrimary Clinical Function
    Ledipasvir USP/Ph.Eur.90 mgGlobal Hepatology Standard: The definitive daily dose required to maintain constant, paralyzing pressure on the NS5A viral protein across the entire 12-to-24 week curative cycle.
    ExcipientsCopovidone / Lactose Monohydrate / Microcrystalline Cellulose / Croscarmellose Sodium / Magnesium Stearate / Premium Opadry FilmSolubility Enhancer / Diluent / Superdisintegrant / Lubricant / Film-Coating (Engineered specifically utilizing Amorphous Solid Dispersion techniques with Copovidone to force the highly insoluble Ledipasvir to dissolve instantly in gastric fluid, guaranteeing maximum systemic bioavailability)

    *Pack Sizes: Bottles of 28 or 10×10 Blisters (Optimized specifically for strict 4-week dispensing intervals to match custom DAA combination regimens).

  • Ribavirin Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu or heavy-density PVC/PVDC blister strips to ensure the stability of the active nucleoside analog and protect handlers from exposure.

    Active IngredientStrengthPrimary Clinical Function
    Ribavirin USP/Ph.Eur.200 mgGlobal Clinical Standard: Base titration unit for precise, weight-based antiviral dosing.
    Ribavirin USP/Ph.Eur.400 mgHigh-dose unit to drastically improve pill-burden compliance in heavy patients.
    ExcipientsMicrocrystalline Cellulose / Croscarmellose Sodium / Povidone / Magnesium StearateDiluent / Superdisintegrant / Binder (Engineered for immediate gastric dissolution and rapid systemic absorption)

    *Pack Sizes: 10×10 Blisters or Bottles of 100 (Optimized specifically for high-dose, weight-based daily regimens requiring 4 to 6 tablets per day).

  • Rifaximin Ph.Eur Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Engineered Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute stability of the crystalline polymorph structure.

    Active IngredientStrengthPrimary Clinical Function
    Rifaximin Ph.Eur.200 mg / 400 mgGI Infection Dose: Acute eradication of non-invasive E. coli (Traveler’s Diarrhea).
    Rifaximin Ph.Eur.550 mgHepatology & IBS Standard: High-dose maintenance therapy for Hepatic Encephalopathy and IBS-D.
    ExcipientsMicrocrystalline Cellulose / Sodium Starch Glycolate / Colloidal Silicon Dioxide / Propylene GlycolDiluent / Superdisintegrant / Glidant / Film-Coating Plasticizer (Engineered for optimal dispersion throughout the intestinal lumen)

    *Pack Sizes: 10×10 Alu-Alu Blisters or 14-Tablet Blisters (Optimized specifically for standard acute infection or chronic hepatology dispensing regimens).

  • Sofosbuvir 400 mg tablet + Ledipasvir 90 mg Tablet

    Free

    A tablet containing Sofosbuvir 400 mg + Ledipasvir 90 mg is a fixed-dose combination antiviral medication used to treat chronic Hepatitis C Virus (HCV) infection, specifically targeting genotypes 1, 4, 5, and 6.

  • Sofosbuvir 400mg+ Velpatasvir 100 mg Tablet

    Free

    Sofosbuvir 400 mg + Velpatasvir 100 mg tablet is a fixed-dose combination antiviral medication used to treat chronic Hepatitis C Virus (HCV) infection across all major genotypes (1 through 6).

  • Sofosbuvir Tablet

    Free

    Sofosbuvir 400 mg tablet is a direct-acting antiviral medication used to treat chronic Hepatitis C Virus (HCV) infection. It belongs to the nucleotide polymerase inhibitor class and works by blocking the NS5B protein, which the virus needs to replicate.